Harry Lamble
Plus aucun poste en cours
Profil
Harry John Lamble is the founder.
He founded Sense Biodetection Ltd.
in 2014, where he held the title of Chief Business Development Officer & Director from 2021 to 2023.
He also founded Fuse Diagnostics Ltd.
in 2022 and currently serves as the Chief Executive Officer.
In addition to his founding positions, Dr. Lamble has worked as Secretary & Director at Oxford BioTherapeutics Ltd.
Furthermore, he holds a doctorate degree from the University of Bath and an MBA from Cranfield University.
Postes actifs de Harry Lamble
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Harry Lamble
| Sociétés | Poste | Fin |
|---|---|---|
Sense Biodetection Ltd.
 Sense Biodetection Ltd. Medical/Nursing ServicesHealth Services Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom. | Fondateur | 30/01/2023 |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Directeur/Membre du Conseil | - |
Formation de Harry Lamble
| University of Bath | Doctorate Degree |
| Cranfield University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Sense Biodetection Ltd.
Sense Biodetection Ltd. Medical/Nursing ServicesHealth Services Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom. | Health Services |
